Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis
Author:
Shi Ting1, Vennard Sophie1, Jasiewicz Francis1, Brogden Rory1, Nair Harish1, Nair Harish, Campbell Harry, Shi Ting, Li You, Openshaw Peter, Beutels Philippe, Bont Louis, Pollard Andrew, Molero Eva, Martinon-Torres Federico, Heikkinen Terho, Meijer Adam, Kølsen Fischer Thea, van den Berge Maarten, Giaquinto Carlo, Abram Michael, Swanson Kena, K Stoszek Sonia, Pircon Jean-Yves, Gallichan Scott, Demont Clarisse, Aerssens Jeroen, Cheret Arnaud, Ispas Gabriela, Peeters Paul, Rosen Brian, Fuentes Robert, Falsey Ann, Mikolajczyk Rafael, Anderson Larry,
Affiliation:
1. Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, Scotland, United Kingdom
Abstract
Abstract
Background
Respiratory syncytial virus related acute respiratory infection (RSV-ARI) constitutes a substantial disease burden in adults with comorbidities. We aimed to identify all studies investigating the disease burden of RSV-ARI in this group.
Methods
We estimated the incidence, hospitalization rate, and in-hospital case fatality ratio (hCFR) of RSV-ARI in adults with comorbidities based on a systematic review of studies published between January 1996 and March 2020. We also investigated the association between RSV-ARI and any comorbidity in adults. Meta-analyses based on random effects model were carried out.
Results
Overall, 20 studies were included. The annual incidence rate of RSV-ARI in adults with any comorbidity was 37.6 (95% confidence interval [CI], 20.1–70.3) per 1000 persons per year in industrialized countries and the seasonal incidence rate was 28.4 (11.4–70.9) per 1000 persons per season. The hCFR in industrialized countries was 11.7% (5.8%–23.4%). There were no studies in developing countries. There were insufficient data to generate the meta-estimate of hospitalization rate. The likelihood of experiencing RSV-ARI for those with any comorbidity compared to those without was estimated to be 4.1 (odds ratio [OR], 1.6–10.4) and 1.1 (OR, 0.6–1.8) from studies using univariable and multivariable analysis respectively.
Conclusion
The disease burden of RSV-ARI among adults with comorbidity is substantial with limited data available.
Funder
Innovative Medicines Initiative 2 European Union European Federation of Pharmaceutical Industries and Associations
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Immunology and Allergy
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|